Vinblastine-Induced Constipation

Mechanism of Action

Vinblastine causes constipation primarily through its pronounced neuropathic effects that prolong gastrointestinal transit time by disrupting normal neuromuscular function in the intestinal tract 1
Vinblastine avidly binds tubulin and prevents microtubule formation, disrupting the normal cytoskeletal structure needed for proper intestinal motility 2
Vinblastine causes pronounced neuropathic effects on the autonomic nervous system that controls intestinal peristalsis, impairing the neural signaling necessary for coordinated bowel movements 1

The severity of constipation varies among vinca alkaloids, with vincristine and vindesine being the most severe, vinblastine being moderate, and vinorelbine being the least severe 1
The constipation caused by vinblastine is characterized by decreased fecal number and water content, reduced bowel movement frequency, harder stool consistency, and is often resistant to standard laxative therapy

Combination therapy with osmotic laxatives and stimulant laxatives is recommended for vinblastine-induced constipation 3
Prophylactic laxative therapy should be considered when starting vinblastine treatment, and bulk-forming laxatives should be avoided in patients with low fluid intake 3
For severe cases, consider peripheral μ-opioid receptor antagonists if other measures fail 3

Untreated constipation can lead to complications including nausea, vomiting, hemorrhoids, anal fissures, and even bowel obstruction 1
Proactive management of vinblastine-induced constipation can reduce hospitalization risk and healthcare burden, and improve patient quality of life and treatment adherence 1